ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101
December 03, 2018Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10). According to Editas, EDIT-101 is -
FDA clears clinical testing of Editas Medicine's gene-editing drug EDIT-101
December 02, 2018Editas Medicine on Friday announced that the FDA has approved the launch of a Phase I/II trial for EDIT-101, an experimental CRISPR genome-editing drug being developed to treat Leber's congenital amaurosis type 10 (LCA10).
Pharma Sources Insight January 2025
